Copyright
©The Author(s) 2015.
World J Nephrol. Jul 6, 2015; 4(3): 406-414
Published online Jul 6, 2015. doi: 10.5527/wjn.v4.i3.406
Published online Jul 6, 2015. doi: 10.5527/wjn.v4.i3.406
Table 1 Demographic and aortic stiffness indices characteristics
Patients characteristics | Study population | Patients with moderately increased albuminuria | Patients with severely increased albuminuria | P value |
No | 115 | 58 | 57 | - |
Age (yr) | 52.6 ± 14.6 | 51.4 ± 14.4 | 54.2 ± 15.07 | NS |
Sex (M/F), (n) | 76/39 | 39/19 | 37/20 | NS |
BMI (kg/m2) | 30.9 ± 19.3 | 28.6 ± 4.5 | 33.9 ± 28.2 | < 0.03 |
Smoking, n (%) | 5 | 3 | 2 | NS |
pSBP (mmHg) | 138.0 ± 14.2 | 139 ± 12.7 | 138.0 ± 15.5 | NS |
pDBP (mmHg) | 84.2 ± 9.7 | 84.9 ± 10.7 | 82.6 ± 9.8 | NS |
pPP (mmHg) | 57.9 ± 15.9 | 56.7 ± 15.1 | 59.4 ± 16.9 | NS |
cSBP (mmHg) | 130.3 ± 14.6 | 130 ± 13.3 | 130.2 ± 16.5 | NS |
cDBP(mmH) | 84.2 ± 9.7 | 84.9 ± 10.7 | 84.3 ± 8.6 | NS |
cPP (mmHg) | 48.1 ± 17.6 | 47.9 ± 17.9 | 48.4 ± 17.8 | NS |
AIx (%) | 21.1 ± 10.6 | 18.4 ± 10.0 | 24.5 ± 10.0 | < 0.004 |
PWVc-f (m/sec) | 8.7 ± 2.0 | 8.3 ± 2.0 | 9.1 ± 1.9 | < 0.02 |
ACEIs, n (%) | ||||
(ramipril or quinapril) | 100 (86) | 56 (96) | 44 (77) | NS |
AT1 RB, n (%) | ||||
(valsartan or olmesartan) | 20 (17.4) | 9 (15.5) | 11 (19.2) | NS |
CCBs, n (%) | 11 (9.5) | 6 (10.3) | 5 (8.7) | NS |
Statins, n (%) | 7 (6.08) | 3 (5.1) | 4 (7.01) | NS |
Table 2 Biochemical characteristics of the study population
Patients characteristics | Study population | Patients with moderately increased albuminuria | Patients with severely increased albuminuria | P value |
No | 115 | 58 | 57 | - |
Ht (%) | 42.3 ± 3.7 | 43.2 ± 3.7 | 41.4 ± 3.5 | 0.01 |
Hb (g/dL) | 13.6 ± 1.3 | 14.1 ± 1.5 | 13.3 ± 1.5 | 0.02 |
Fe (μg/dL) | 89 ± 35.5 | 90.2 ± 30 | 84.2 ± 38.5 | NS |
Ferritin (ng/L) | 127.4 ± 90.1 | 127.8 ± 87.9 | 131.3 ± 96.5 | NS |
Fibrinogen (mg/dL) | 336 ± 82.9 | 339 ± 86.5 | 394 ± 133.9 | < 0.01 |
hsCRP (mg/dL) | 0.19 ± 0.06 | 0.18 ± 0.05 | 0.23 ± 0.10 | < 0.001 |
T-CHOL (mg/dL) | 203 ± 37.5 | 208 ± 39.2 | 209 ± 46.8 | NS |
TRG (mg/dL) | 126 ± 45.7 | 123 ± 46.3 | 145 ± 70.2 | 0.05 |
HDL-C (mg/dL) | 53.4 ± 13.3 | 53 ± 12.9 | 54.2 ± 14.9 | NS |
LDL-C (mg/dL) | 119 ± 32 | 120 ± 3.7 | 121 ± 3.6 | NS |
Ca2+ (mg/dL) | 9.7 ± 0.4 | 9.7 ± 0.5 | 9.8 ± 0.4 | NS |
PO43- (mg/dL) | 3.42 ± 0.4 | 3.3 ± 0.4 | 3.5 ± 0.5 | 0.01 |
Ca2+ x PO43- | 33.7 ± 4.8 | 32.6 ± 4.5 | 33.9 ± 8.6 | NS |
PTH (pg/mL) | 42.4 ± 15.4 | 39.8 ± 13.6 | 45.4 ± 29.9 | NS |
sAlb (gr/dL) | 4.5 ± 0.2 | 4.5 ± 0.3 | 4.3 ± 0.5 | 0.03 |
eGFR-MDRD (mL/min per 1.73 m2) | ||||
92 ± 0.5 | 91.5 ± 20.5 | 79.1 ± 15.3 | < 0.001 | |
CKD-EPI(mL/min per 1.73 m2) | ||||
73.4 ± 1.25 | 73.1 ± 13.7 | 73.6 ± 11.2 | NS | |
Table 3 Univariate linear regression analysis of the parameters associated with the absolute values of pulse wave velocity
Covariates | β | t | β(95%CI) | P value |
Alb | 0.841 | 2.271 | 0.107-1.574 | < 0.025 |
Age | 0.026 | 2.047 | 0.001-0.051 | < 0.043 |
BMI | 0.009 | 0.880 | 0.011-0.028 | 0.381 |
pSBP | 0.032 | 2.511 | 0.007-0.058 | < 0.013 |
pDBP | 0.005 | 0.285 | -0.032-0.042 | < 0.776 |
pPP | 0.029 | 2.277 | 0.004-0.053 | < 0.025 |
cSBP | 0.031 | 2.298 | 0.004-0.508 | < 0.024 |
cDBP | -0.004 | -0.173 | -0.045-0.038 | 0.963 |
cPP | 0.014 | 1.257 | 0.008-0.037 | 0.212 |
Ht | 0.103 | 2.077 | 0.005-0.202 | 0.040 |
Hb | 0.227 | 1.812 | 0.020-0.476 | 0.070 |
T-CHOL | 0.021 | 0.456 | -0.011-0.007 | 0.649 |
TRG | 0.002 | 0.752 | 0.009-0.004 | 0.454 |
HDL-C | -0.006 | -0.417 | -0.033-0.022 | 0.677 |
LDL-C | 0.023 | 0.445 | 0.013-0.477 | 0.674 |
Fbrinogen | 0.0001 | 0.524 | -0.004-0.002 | 0.602 |
hsCRP | -0.011 | 0.046 | -0.442-0.422 | 0.964 |
RAAS-blocker | 0.081 | -0.103 | -1.650-1.487 | 0.918 |
Table 4 Multivariate linear regression analysis of the parameters associated with the absolute values of pulse wave velocity
Covariates | β | t | β(95%CI) | P value |
UAlb | 1.038 | 2.638 | 0.257-1.820 | < 0.010 |
pSBP | 0.028 | 2.149 | 0.002-0.053 | < 0.034 |
Ht | 0.171 | 3.319 | 0.069-0.273 | < 0.001 |
Table 5 Univariate linear regression analysis of the parameters associated with absolute values of Alx
Covariates | β | t | β(95%CI) | P value |
UAlb | 6.201 | 2.977 | 2.065-10.337 | < 0.004 |
Age | 0.236 | 3.427 | 0.099-0.373 | < 0.0001 |
BMI | 0.036 | 0.667 | 0.070-0.142 | 0.507 |
pSBP | 0.291 | 4.427 | 0.161-0.422 | < 0.0001 |
pDBP | 0.001 | 0.002 | -0.216-0.216 | < 0.002 |
pPP | 0.278 | 4.536 | 0.156-0.400 | < 0.0001 |
cSBP | 0.349 | 5.518 | 0.223-0.474 | < 0.0001 |
cDBP | -0.045 | -0.401 | 0.265-0.176 | 0.689 |
cPP | 0.265 | 4.912 | 0.558-0.372 | < 0.0001 |
Ht | -0.848 | 0.002 | -1.382-0.314 | < 0.002 |
Hb | -0.599 | -0.826 | -2.040-0.841 | 0.411 |
T-CHOL | 0.050 | 1.836 | -0.041-0.042 | 0.069 |
TRG | 0.021 | 1.164 | 0.015-0.057 | 0.247 |
HDL-C | 0.104 | 1.318 | -0.534-0.035 | 0.262 |
LDL-C | 0.047 | 1.265 | -0.045-0.052 | 0.243 |
Fbrinogen | 0.007 | 0.749 | -0.122-0.273 | 0.456 |
hsCRP | 0.015 | 0.732 | -1.738-3.768 | 0.466 |
RAAS-blocker | 1.043 | 0.139 | 13.881-15.966 | 0.890 |
Table 6 Multivariate linear regression analysis of the parameters associated with the absolute values of Al
Covariates | β | t | β(95%CI) | P value |
UAlb | 4.385 | 2.557 | 1.023-8.146 | < 0.012 |
cSBP | 0.242 | 3.563 | 0.107-0.376 | < 0.0001 |
cPP | 0.147 | 2.623 | 0.036-0.259 | < 0.0001 |
Ht | 0.591 | 2.536 | 1.055-0.128 | < 0.013 |
- Citation: Kalaitzidis RG, Karasavvidou DP, Tatsioni A, Pappas K, Katatsis G, Liontos A, Elisaf MS. Albuminuria as a marker of arterial stiffness in chronic kidney disease patients. World J Nephrol 2015; 4(3): 406-414
- URL: https://www.wjgnet.com/2220-6124/full/v4/i3/406.htm
- DOI: https://dx.doi.org/10.5527/wjn.v4.i3.406